Optimal Resection Technique for Medium-sized (10-20mm) Colorectal Polyps
Launched by UNITY HEALTH TORONTO · Apr 27, 2023
Trial Information
Current as of August 19, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the best way to remove medium-sized colorectal polyps, which are growths found in the colon that can sometimes lead to cancer if not treated. The researchers want to compare three different methods of removal: Endoscopic Mucosal Resection (EMR), cold EMR, and underwater EMR. By studying these methods, they hope to find out which one results in fewer cases of the polyps coming back and has fewer side effects for patients.
To be eligible for this trial, participants need to be at least 18 years old, have a specific type of polyp that measures between 10 to 20 mm, and complete the bowel preparation recommended by their doctor. It’s important to note that certain conditions, like inflammatory bowel disease or pregnancy, would exclude someone from participating. If someone joins the trial, they can expect to undergo one of the removal techniques under careful monitoring to ensure their safety and well-being throughout the process. This study is not yet recruiting participants, but it aims to improve how we treat these types of polyps in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. The patient (or a legally authorized representative) provides informed consent
- • 2. 18 years of age or older
- • 3. Completion of the endoscopist-recommended bowel preparation
- 4. Presence of one eligible medium-sized polyp:
- • 10-20 mm in size
- • Paris classification of 0-IIa (flat, elevated lesion) on standard white light colonoscopy
- • JNET Type 1 or 2A on magnifying Narrow Band Imaging (NBI) suspecting a sessile serrated lesion, adenoma, or adenoma with low-grade dysplasia.
- Exclusion Criteria:
- • 1. Patient \< 18 years old
- • 2. Inability to provide informed consent
- • 3. Inflammatory Bowel Disease,
- • 4. Familial Polyposis
- • 5. Pregnancy
- • 6. Incomplete bowel preparation
- 7. Patients with ineligible lesion:
- • Paris classification of 0-Ip or 0-Is on standard white light colonoscopy,
- • JNET Type 1 suspecting a hyperplastic polyp, or Type 2B or 3 suspecting a high- grade dysplasia or adenocarcinoma.
About Unity Health Toronto
Unity Health Toronto is a leading healthcare organization dedicated to providing exceptional patient care, advancing medical research, and fostering education in the field of health sciences. Comprising St. Michael's Hospital, St. Joseph's Health Centre, and Providence Healthcare, Unity Health integrates a diverse range of clinical services and innovative research initiatives. The organization is committed to improving health outcomes through collaborative partnerships and community engagement, while upholding the highest standards of ethics and integrity in its clinical trials and research endeavors. By focusing on patient-centered approaches, Unity Health Toronto aims to drive advancements in healthcare and contribute to the well-being of the communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kareem Khalaf, HBSc, MD
Study Director
Unity Health Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported